SGNMesoC2-001: A Study of SGN-MesoC2 in Advanced Solid Tumors (clinicaltrials.gov) - Jun 25, 2026 - P1 | N=19 | Terminated | Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: May 2029 ➔ May 2026 | Active, not recruiting ➔ Terminated | Trial primary completion date: May 2028 ➔ May 2026; The trial was terminated for strategic reasons. The decision was not based on any safety concerns
Trial completion date • Trial primary completion date • Trial termination • Colorectal Cancer • Endometrial Cancer • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor
|